{"id":"candesartan-hctz-phase-1","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Dizziness"},{"rate":"3-8%","effect":"Fatigue"},{"rate":"5-15%","effect":"Hyperuricemia"},{"rate":"5-10%","effect":"Hypokalemia"},{"rate":"3-7%","effect":"Headache"},{"rate":"1-3%","effect":"Cough"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Candesartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels and the heart, causing vasodilation and reduced blood pressure. Hydrochlorothiazide (HCTZ) is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urine output and reducing blood volume. The combination provides complementary antihypertensive effects through different mechanisms.","oneSentence":"Candesartan blocks angiotensin II receptors to lower blood pressure, while HCTZ is a thiazide diuretic that reduces fluid volume and sodium reabsorption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:55.410Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT01198496","phase":"PHASE4","title":"Recurrent Stroke Prevention Clinical Outcome Study","status":"UNKNOWN","sponsor":"Biomedis International Ltd.","startDate":"2010-10","conditions":"Hypertension, Stroke, Blood Pressure","enrollment":5000},{"nctId":"NCT00867490","phase":"PHASE3","title":"Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-03","conditions":"Hypertension","enrollment":186},{"nctId":"NCT00434967","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-01","conditions":"Hypertension","enrollment":2207},{"nctId":"NCT00621153","phase":"PHASE4","title":"Candesartan Effect in Second Stage Arterial Hypertension","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-02","conditions":"Stage II Hypertension","enrollment":214},{"nctId":"NCT00383929","phase":"PHASE3","title":"Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Hypertension","enrollment":1979}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Candesartan+HCTZ - Phase 1","genericName":"Candesartan+HCTZ - Phase 1","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Candesartan blocks angiotensin II receptors to lower blood pressure, while HCTZ is a thiazide diuretic that reduces fluid volume and sodium reabsorption. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}